This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Albireo Pharma Toekomstige groei
Future criteriumcontroles 2/6
Belangrijke informatie
62.9%
Groei van de winst
61.4%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.9% |
| Inkomstengroei | 51.1% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 24 Feb 2023 |
Recente toekomstige groei-updates
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2025 | 248 | -5 | N/A | N/A | 5 |
| 12/31/2024 | 128 | -102 | N/A | N/A | 5 |
| 12/31/2023 | 61 | -144 | N/A | N/A | 7 |
| 12/31/2022 | 35 | -159 | N/A | N/A | 7 |
| 9/30/2022 | 57 | -131 | -116 | -115 | N/A |
| 6/30/2022 | 51 | -36 | -114 | -113 | N/A |
| 3/31/2022 | 45 | -33 | -109 | -108 | N/A |
| 12/31/2021 | 41 | -34 | -108 | -108 | N/A |
| 9/30/2021 | 11 | -48 | -122 | -122 | N/A |
| 6/30/2021 | 9 | -136 | -121 | -120 | N/A |
| 3/31/2021 | 9 | -120 | -112 | -112 | N/A |
| 12/31/2020 | 8 | -108 | -101 | -101 | N/A |
| 9/30/2020 | 12 | -90 | -85 | -85 | N/A |
| 6/30/2020 | 11 | -82 | -73 | -73 | N/A |
| 3/31/2020 | 11 | -78 | -64 | -63 | N/A |
| 12/31/2019 | 10 | -63 | -53 | -53 | N/A |
| 9/30/2019 | 4 | -71 | -51 | -51 | N/A |
| 6/30/2019 | 3 | -63 | -47 | -47 | N/A |
| 3/31/2019 | 2 | -61 | -41 | -41 | N/A |
| 12/31/2018 | 13 | -46 | -27 | -27 | N/A |
| 9/30/2018 | 12 | -35 | -25 | -25 | N/A |
| 6/30/2018 | 12 | -28 | -20 | -20 | N/A |
| 3/31/2018 | 11 | -19 | -18 | -18 | N/A |
| 12/31/2017 | 0 | -24 | -28 | -28 | N/A |
| 9/30/2017 | 3 | -31 | -26 | -26 | N/A |
| 6/30/2017 | 3 | -28 | -25 | -25 | N/A |
| 3/31/2017 | 11 | -20 | -15 | -15 | N/A |
| 12/31/2016 | 11 | -16 | -9 | -9 | N/A |
| 9/30/2016 | 13 | -5 | -1 | -1 | N/A |
| 6/30/2016 | 13 | -4 | N/A | 1 | N/A |
| 3/31/2016 | 5 | -8 | N/A | -5 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ALBO is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ALBO is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ALBO is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ALBO's revenue (51.1% per year) is forecast to grow faster than the US market (6.9% per year).
Hoge groei-inkomsten: ALBO's revenue (51.1% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time